Selegiline to Zelapar Switch Study in Parkinson Disease Patients

Completed · Phase 4

Conditions studied: Parkinson's Disease

In brief

Parkinson's disease (PD) is a progressive neurodegenerative disease. Symptomatic therapy is primarily aimed at restoring dopamine function in the brain. Oral selegiline in conjunction with L-dopa has been a mainstay of therapy for PD patients experiencing motor fluctuations for many years. The mechanisms accounting for selegiline's beneficial adjunctive action in the treatment of PD are not fully understood. Inhibition of monoamine oxidase (MAO) type B (MAO-B) activity is generally considered to be of primary importance. Oral selegiline has low bio-availability and is typically dosed BID, for a total of 5-10 mg daily. Recently, the FDA approved a new orally disintegration tablet (ODT) formulation of selegiline, called ZelaparTM. This new formulation utilizes Zydis technology to dissolve in the mouth, with absorption through the oral mucosa, thereby largely bypassing the gut and avoiding first pass hepatic metabolism. This allows more active drug to be delivered at a lower dose. Consequently, Zelapar is dosed once-daily, up to 2.5 mg per day. There are no empirical data indicating whether the use of the new approved formulation of selegiline ODT (Zelapar) is superior or preferred by patients compared to traditional oral selegiline. It is believed that clinical efficacy will be preserved or enhanced, by delivering more active drug, with improved patient preference for the ODT formulation due to the once-daily dosing . The effectiveness of orally disintegrating selegiline as an adjunct to carbidopa/levodopa in the treatment of PD was established in a multicenter randomized placebo-controlled trial (n=140; 94 received orally disintegrating selegiline, 46 received placebo) of three months' duration. Patients randomized to orally disintegrating selegiline received a daily dose of 1.25 mg for the first 6 weeks and a daily dose of 2.5 mg for the last 6 weeks. Patients were all treated with levodopa and could additionally have been on dopamine agonists, anticholinergics, amantadine, or any combination of these during the trial. At 12 weeks, orally disintegrating selegiline-treated patients had an average of 2.2 hours per day less "OFF" time compared to baseline. Placebo treated patients had 0.6 hours per day less "OFF" time compared to baseline. These differences were significant (p \< 0.001). Adverse events were very similar between drug and placebo.

Key facts

Study ID: NCT00640159
Run by: Baylor College of Medicine
People needed: 48
Starts: 2007-01-01
Expected to finish: 2008-08-01
Last updated by the study team: 2023-08-09

Who can join

Age: 30 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Idiopathic PD confirmed by at least two of the following signs: resting tremor, bradykinesia, rigidity
Male or female outpatients
Age 30-90 years
Current use of levodopa and oral selegiline (5-10 mg /day), stable for at least 1 month and well tolerated
Positive treatment response to current anti-parkinsonian medications in the opinion of the investigator
Acceptable contraception for females of child bearing potential
Willing and able to comply with study procedures.
Willing and able to give written informed consent prior to beginning any study procedures.

You may not qualify if…

Atypical parkinsonism due to drugs, metabolic disorders, encephalitis, trauma, or other neurodegenerative diseases.
Significant cognitive or psychiatric impairment which, in the opinion of the investigator, would interfere with the ability to complete all the tests required in the protocol.
Participation in another clinical drug trial within the previous four weeks.
Patients on any medications contraindicated with Zelapar (including meperidine/Demerol, tramadol, methadone, propoxyphene, dextromethorphan, other selegiline products)
Patients with a known hypersensitivity to any formulation of selegiline or any of the inactive ingredients of Zelapar, or previous exposure to orally disintegrating selegiline
History of melanoma
Unstable/uncontrolled medical problems
History of drug/alcohol abuse
Patients currently taking rasagiline

Where it is running

Dee Silver, MD at Coastal Neurological Medical Group, Inc — La Jolla, California, United States
James Tetrud, MD at The Parkinson's Institute — Sunnyvale, California, United States
Stuart Isaacson, MD at Parkinson's Disease and Movement Disorder Center of Boca Raton — Boca Raton, Florida, United States
R. Malcolm Stewart, MD at Neurology Specialists of Dallas — Dallas, Texas, United States
PDCMDC 6550 Fannin, Suite 1801 — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.